ArticleJournal of translational medicine2026
Developing an antibody drug encapsulation nanoagent targeting HER2 for cancer treatment.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Beyond ADCs: Antibody-encapsulated drug for targeted cancer therapy.Cell investigation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundHuman epidermal growth factor receptor 2 (HER2) is overexpressed in 15–20% of breast cancer and some other cancers. Trastuzumab (Tr)-based antibody drug conjugates (ADCs) have emerged as a new class of anti-HER2 therapies. However, traditional ADCs face challenges including limited in vivo stability, inefficient drug release, and manufacturing complexities.
methodsWe developed Tr-ACT2, a first-in-class antibody drug encapsulation nanoagent, using single protein encapsulation technology. Tr-ACT2 was characterized by UV absorbance/fluorescence emission spectroscopy, membrane dialysis, particle size distribution, and molecular docking studies. In vitro cellular uptake and cytotoxicity were evaluated in breast and lung cancer cell lines using cell viability assays, western blotting, apoptosis assays, and immunofluorescence. In vivo toxicity was assessed using the A549 xenograft mouse model treated with Tr-ACT2 or irinotecan.
resultsAs a potential antibody-encapsulated drug (AED), Tr-ACT2 features each Tr protein encapsulating two actinomycin D (ACT) molecules without chemical conjugation and linkers. Tr-ACT2 exhibited time-dependent internalization into breast and lung cancer cells with various HER2 expression levels. It led to inhibition of cell growth, induction of apoptosis, and reduction of Akt activation. Notably, Tr-ACT2’s cytotoxic activity appeared to be independent of HER2 expression levels. In a human lung cancer xenograft mouse model, intravenous administration of Tr-ACT2 demonstrated a significant anticancer therapeutic efficacy.
conclusionsThese findings support further evaluation of Tr-ACT2 for the treatment of human cancers. The AED approach may be broadly applicable to other antibodies and chemotherapeutic agents, potentially opening a new avenue for developing targeted anticancer therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.